Volume 49, No. 1/2011(January)
The online-version will be updated before the print-version of this Journal is published. Upon request we will send the password and user name by e-mail. The online-service is only available for subscribers of the print-version, if proof of purchase is submitted.
The use of the online-version will be charged with an extra fee (additional to the subscription of the print-version). The service can be used until December 31st of the year of subscription.
|
| Price of the complete print-issue: 30.00$ |
Add to Cart
|
Editorial
E. von Stebut and K. Steinbrink
Page No. 1
Abstract
Editorial
E. von Stebut and K. Steinbrink
Original
The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment
A.I. Nichols, L.S. Richards, J.A. Behrle, J.A. Posener, S.B. McGrory and J. Paul
Price
42.00 $
Page No. 3
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (3-13)
The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment
A.I. Nichols1, L.S. Richards, J.A. Behrle2, J.A. Posener1, S.B. McGrory1 and J. Paul1
1Pfizer Inc., formerly Wyeth Research, Collegeville, PA, and 2Centocor R&D, Horsham, PA, USA
Background: Desvenlafaxine (administered as desvenlafaxine succinate), the major active metabolite of venlafaxine, is a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Objective: To assess the pharmacokinetics, safety, and tolerability of desvenlafaxine in healthy volunteers vs. those with renal impairment. Materials and methods: A single, oral, 100 mg dose of desvenlafaxine was administered to healthy subjects (n = 8) and subjects with mild (n = 9), moderate (n = 9), or severe (n = 7) renal impairment (24-h creatinine clearance, ml/min: 50 – 80, 30 – 50, or < 30 ml/min, respectively) or end-stage renal disease (ESRD; on dialysis <= 30 days, n = 10). Disposition of (R)-, (S)-, and (R+S)-desvenlafaxine was examined in plasma and urine for 72 h postdosing in healthy patients and 144 h postdosing in patients with renal impairment. For renally impaired subjects, geometric least squares mean (GLSM) ratios (vs. healthy controls as reference) and 90% confidence intervals (CIs) were calculated for area under the plasma concentration-versus-time curve (AUC), peak plasma concentration (Cmax), and apparent oral-dose clearance (Cl/F). Safety was evaluated based on adverse events (AEs), physical examination, 12-lead electrocardiograms, vital signs, and laboratory assessments. Results: GLSM ratios (90% CIs) for AUC were 142% (94.4 – 213%), 156% (103 – 237%), 208% (135 – 322%), and 216% (143 – 324%) among those with mild, moderate, or severe renal impairment, or ESRD, respectively. GLSM ratios (90% CIs) for Cl/F were 71.2% (48.8 – 104%), 61.1% (41.4 – 90.2%), 48.8% (32.6 – 73.0%) and 42.2% (28.9 – 61.6%) for mild, moderate, severe renal impairment and ESRD, respectively. Cmax and time to Cmax were not significantly different among the groups; elimination half-life was prolonged in those with renal impairment. Pharmacokinetic parameters were similar between (R)- and (S)-desvenlafaxine, regardless of renal function. Urinary recovery of total desvenlafaxine was unchanged vs. healthy subjects. Desvenlafaxine was generally well tolerated. Conclusions: Desvenlafaxine 100 mg/d, twice the recommended therapeutic dose for MDD, was generally safe and well tolerated in healthy and renally impaired subjects. Dosage adjustment for desvenlafaxine is recommended in patients with severe renal impairment or ESRD.Correspondence to:
A.I. Nichols, PhD
Pfizer Inc.
500 Arcola Road
Collegeville, PA 19426, USA
Email: [email protected]
Original
An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital
Y.-L. Dong, H.-Y. Dong, S.-S. Hu, X. Wang, Y.-X. Wei, M.-Y. Wang, W.-H. Dong, H.-P. Yao, H.-S. You and J.-F. Xing
Price
42.00 $
Page No. 14
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (14-22)
An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital
Y.-L. Dong1, H.-Y. Dong1, S.-S. Hu1, X. Wang2, Y.-X. Wei1, M.-Y. Wang1, W.-H. Dong1, H.-P. Yao1, H.-S. You1 and J.-F. Xing3
1Department of Pharmacy, 2Department of Central ICU, The First Affiliated Hospital, Medical College, and 3Department of Pharmacy, Medical College, Xi’an JiaoTong University, Xi’an, China
Objective: To validate a high performance liquid chromatography (HPLC) method for serum teicoplanin measurement and use the method for clinical monitoring of teicoplanin levels to analyze the clinical application of teicoplanin. Methods: 55 patient profiles were collected and analyzed for the clinical teicoplanin application. 10 critically ill patients of the 55 cases were monitored for teicoplanin trough concentration using the HPLC method. Results: The modified HPLC method exhibited excellent linearity, with correlation coefficient r = 0.9995. The intra-day and inter-day coefficients of variation were less than 10%. The lower limit of detection of teicoplanin was 5.63 mg/l. The recovery of teicoplanin was above 90%. Of the 55 patients in this study, there were 42 patients without load-dosing. There were only 29 patients treated with teicoplanin documented Gram-positive infections by etiological diagnoses. In the 10 patients with teicoplanin serum trough concentration monitoring, all cases received a loading dose of 400 mg every 12 h for 3 doses, and the mean trough concentration of teicoplanin was 10.82 ± 4.51 mg/l. The mean trough levels were 13.04 ± 6.23 mg/l in 4 patients with microbiological eradication and improvement of symptoms of diseases and 9.34 ± 2.61 mg/l in 6 patients with persistence of previous clinical infectious symptoms, respectively. Conclusion: The modified HPLC method is robust, highly reproducible and suited to monitor the concentration of teicoplanin. In critically ill Chinese patients, we should consider more appropriate loading doses and evaluate the relationship between teicoplanin trough concentration and the efficacy using microbiological and clinical parameters.Correspondence to:
Y.-L. Dong, PhD
Department of Pharmacy
The First Affiliated Hospital
Medical College
Xi’an JiaoTong University, Xi’an, 710061, China
Email: [email protected]
Original
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation
J. Yang, C. Huang, Z. Shen and L. Miao
Price
42.00 $
Page No. 23
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (23-29)
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation
J. Yang1, C. Huang2, Z. Shen3 and L. Miao2
1Institute of Cardiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 2Department of Clinical Pharmacology Research Lab, and 3Department of Cardiovascular Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Objective: The objective was to assess 1173C > T polymorphism of the VKORC1 gene and its contribution to warfarin dose requirements in Han Chinese patients. Methods: Blood samples were collected from 178 patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the target range (1.5 – 3.0). Polymorphisms for VKORC1 (1173C > T), CYP2C9, venous INR, and plasma concentration and unbound concentration of warfarin were analyzed. Results: VKORC1 (1173C > T) genotyping showed that 154 patients were homozygous TT, 23 were heterozygous CT, and one was homozygous for the CC genotype. Patients with the VKORC1 (1173CC + CT) genotype required a significantly higher warfarin dose (3.33 ± 1.04 mg/day) than those with 1173TT (1.81 ± 0.63 mg/day; p < 0.001). The multiple linear regression model for warfarin dose indicated significant contributions from the VKORC1 (1173C > T) genotype (r2 = 0.355; p < 0.001), and age, body weight, and CYP2C9 and VKORC1 genotype together (r2 = 0.513; p < 0.001). The two SNPs (–1639 and 1173) were found to be in very strong linkage disequilibrium with estimated D’ = 0.96 (95%CI (0.83 – 0.99)). Conclusion: The VKORC1 (1173C > T) polymorphism might be very important, and its contribution can be equally explained by the VKORC1(–1639 G > A) polymorphism for warfarin dose requirements in Han Chinese patients.Correspondence to:
L. Miao
Department of Clinical Pharmacology Research Lab
First Affilated Hospital of Soochow University
Suzhou, Jiangsu, China
Email: [email protected]
Original
The possibility of using the specific RIA method for the area-under-time-concentration curve sparse sampling calculation of cyclosporin A despite a large post-dose overestimation
M. Grundmann, B. Koristkova, H. Brozmanova, I. Perinova and K. Safarcik
Price
42.00 $
Page No. 30
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (30-37)
The possibility of using the specific RIA method for the area-under-time-concentration curve sparse sampling calculation of cyclosporin A despite a large post-dose overestimation
M. Grundmann1, B. Koristkova1, H. Brozmanova1, I. Perinova1 and K. Safarcik2
1Department of Clinical Pharmacology and 2Nuclear Medicine Clinic, Ostrava University Hospital and Medical Faculty, University of Ostrava, Ostrava, Czech Republic
Objective: To find limited sampling strategies (LSS) for prediction of the real AUC using the RIA analytical method. Method: Blood samples of 40 male renal transplant patients taken pre-dose and after 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h in the steady-state were analyzed with HPLC and the specific RIA method. I. Eight equations for AUC0–12 and one for AUC0–8 obtained from the literature, that produced the mean percentage prediction error (%PE) < ± 15% and absolute %PE < 30% in 95% of predictions, were analyzed for possibility to predict the real AUC of CsA. II. Multiple regression analysis (MRA) was provided for the AUC equation proposal. Patients were divided into two groups according to the AUC0–12. Group I was used for LSS : s proposals while Group II for validation. The bias and precision were expressed as %PE, r2 and RMSE. The relationship of %PE interassay and with LSS:s was expressed as Pearson correlation r. GraphPad InStatt Software was used for MRA and Pearson r calculation. Results: None of the equations described in the literature predicts AUC of CsA proprietarily. Seven equations for AUC0–12 and five for AUC0–8 were proposed with MRA for prediction of real AUC from RIA values. Conclusions: LSS:s can moderate the interassay %PE in AUC of CsA. New patients should be tested with both RIA and HPLC for the level of overestimation. The conversion factors should be calculated for patients with an overestimation higher than 90%. Our equation 251.09 + 0.5195 × C1h + 4.926 × C3h or 196.13 + 4.526 × C0h + 2.089 × C1.5h for AUC0–12, and 171.80 + 0.4759 × C1h + 4.132 × C3h for AUC0–8 may be used in patients with medium or low RIA and HPLC differences. Repeated analysis with HPLC is thus suggested in cases with AUC:s results close to the lower or upper margin of the therapeutic window.Correspondence to:
M. Grundmann, AssocProf, MD, PhD
Department of Clinical Pharmacology
Ostrava University Hospital and Medical Faculty
University of Ostrava
17. listopadu 1790
CZ 708 52 Ostrava, Czech Republic
Email: [email protected]
Case Report
Subacute liver failure induced by adalimumab
S. Hagel, T. Bruns, B. Theis, A. Herrmann and A. Stallmach
Price
42.00 $
Page No. 38
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (38-40)
Subacute liver failure induced by adalimumab
S. Hagel1, T. Bruns1, B. Theis2, A. Herrmann1 and A. Stallmach1
1Division of Gastroenterology, Hepatology and Infectious Disease, Department of Internal Medicine II, and 2Department of Pathology, Friedrich-Schiller-University, Jena, Germany
Most cases of liver toxicity associated with TNF-antagonists have been linked to infliximab and to a lesser extent to etanercept. So far only mild elevations of liver enzymes during therapy with adalimumab have been reported. In general, patients who developed ALT and AST elevations were asymptomatic and the abnormalities decreased or resolved with either continuation or discontinuation of adalimumab, or modification of concomitant medications. In this case report, we are presenting the first case of a patient without previous history of liver disease or concomitant risk factors for liver disease who developed subacute liver failure during therapy with adalimumab for psoriatic arthritis.Correspondence to:
Dr. S. Hagel
Department of Internal Medicine II
Division of Gastroenterology, Hepatology and
Infectious Disease
Friedrich-Schiller-University
Erlanger Allee 101, 07740 Jena, Germany
Email: [email protected]
Original
Erdosteine affects eicosanoid production in COPD
R.W. Dal Negro, M. Visconti, S. Tognella and C. Micheletto
Price
42.00 $
Page No. 41
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (41-45)
Erdosteine affects eicosanoid production in COPD
R.W. Dal Negro, M. Visconti, S. Tognella and C. Micheletto
Lung Department, Orlandi General Hospital, Bussolengo, Verona, Italy
Oxidant-antioxidant imbalance and lipid peroxidation are known to activate the 5-LO pathway with increased expression of inflammatory eicosanoids. Erdosteine has recently shown important anti-oxidant properties, including the ability to reduce 8-isoprostane in COPD patients. Aim: To assess the effects of erdosteine (E) on eicosanoids, and to compare the time-course of effect with that of E anti-oxidant activity. Methods: 12 moderate COPD patients (9 males, 60 – 78 y) randomly received E 300 mg b.i.d. or placebo (P) for 10 days in a double-blind, controlled design. Blood ROS (Fort/Units); serum LTB4 and urine LTE4 (pg/ml) were measured at baseline and after 1, 3, 5 and 10 days of treatment. Analysis of covariance (ANCOVA) was performed. Results: In COPD patients, both LTB4 and LTE4 dropped significantly during the 10-day treatment with E: s-LTB4 from 136.0 ± 35.4 SD to 54.5 ± 31.2 SD; u-LTE4 from 267.0 ± 91.5 SD to 84.0 ± 64.7 SD, p < 0.001 vs. p from Days 5 and 3, respectively. Moreover, a significant decrease of blood ROS was confirmed in patients using E. FEV1 values slightly increased during erdosteine treatment, whereas a trend to decrease was observed in the placebo group, with a significant difference in favor of erdosteine after 10 days of treatment (p = 0.0088). Conclusions: 1) The scavenging and anti-inflammatory effects of Erdosteine were both confirmed; 2) erdosteine proved to affect eicosanoids significantly; 3) this novel effect underlines the important anti-inflammatory potentialities of the drug in COPD; 4) further investigation is needed in order to assess the capability of Erdosteine in controlling ongoing inflammation in chronic respiratory diseases.Correspondence to:
R.W. Dal Negro
Orlandi General Hospital
Via Ospedale, 37012 Bussolengo, Italy
Email: [email protected]
Case Report
Toxic dermatitis in patients treated with Taxotere® (docetaxel): three case reports
B. van Oijen, M. Pleunis, F. Erdkamp, R. Prevoo and H. van der Kuy
Price
42.00 $
Page No. 46
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (46-48)
Toxic dermatitis in patients treated with Taxotere® (docetaxel): three case reports
B. van Oijen1, M. Pleunis2, F. Erdkamp2, R. Prevoo3 and H. van der Kuy1
1Department of Pharmacology and Toxicology, 2Department of Hematology and Oncology, and 3Department of Dermatology, Orbis Medical Center, Sittard, The Netherlands
Three out of 25 patients receiving the same batch docetaxel, developed toxic dermatitis within 5 days after administration. Timing of occurrence was equal and symptoms were similar. Two patients continued with docetaxel without any problems. There is no assignable cause found that could explain the toxic dermatitis.Correspondence to:
B. van Oijen
Department of Pharmacology and Toxicology
Orbis Medical Center
Dr. H. van der Hoffplein 1
6162 BG Sittard – Geleen, The Netherlands
Email: [email protected]
Case Report
Minocycline-induced chemical pneumonitis and its successful treatment: a case report
H.-W. Shih, S.-L. Cheng, S.-C. Chang and C.-Y. Chang
Price
42.00 $
Page No. 49
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (49-50)
Minocycline-induced chemical pneumonitis and its successful treatment: a case report
H.-W. Shih1, S.-L. Cheng1, S.-C. Chang2 and C.-Y. Chang1
1Department of Chest Medicine, Far Eastern Memorial Hospital, and 2Internal Medicine, National Yang-Ming University Hospital, Taipei, Taiwan
Chemical pleurodesis is an effective treatment for persistent air leakage and secondary pneumothorax. We report the case of a 57-year-old man who presented with pneumothorax and was treated by tube thoracostomy. Because of malpositioning of the chest tube, the minocycline that was administered for pleurodesis was injected into the lung parenchyma instead, which induced chemical pneumonitis. A review of literature indicated that this is the first report of minocycline-associated chemical pneumonitis and its successful treatment.Correspondence to:
Dr. C.-Y. Chang
Department of Chest Medicine
Far Eastern Memorial Hospital
21, Nan-Ya S. Rd., Sec.2
Pan-Chiao, Taipei, Taiwan
Email: [email protected]
Bioavailability Section
High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast
T.D. Bethke and G. Lahu
Price
42.00 $
Page No. 51
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 49 – No. 1/2011 (51-57)
High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast
T.D. Bethke and G. Lahu
Nycomed GmbH, Konstanz, Germany
Objective: To establish basic intravenous (IV) pharmacokinetics of roflumilast (ROF) and its pharmacologically active metabolite roflumilast N-oxide (R-NO) and to determine the absolute bioavailability of ROF in humans. Materials: In a randomized, open-label, 2-period, 2-sequence crossover study 12 healthy male subjects were randomized to receive ROF either orally (PO) 500 µg (immediate release tablets) or single IV (150 µg over 15 min). Plasma concentrations were determined. Dose-adjusted point estimates and 90% confidence intervals (CI) were calculated for the ratio of the AUC time curves using a multiplicative model and parametric analysis. Results: After IV administration, clearance of ROF was 0.14 l/h/kg, volume of distribution (Vd area) 2.92 l/kg, and the terminal t1/2 was 14.8 h. After PO administration, ROF was rapidly absorbed; the absolute bioavailability was 79%. The AUC of the R-NO metabolite generally exceeded that of ROF. After IV and PO administration, the metabolic ratios were 7.4 and 12.4, respectively. Dose-adjusted analysis of the R-NO AUC values indicate a 21% higher R-NO formation seen with PO vs. IV, suggesting entire first-pass conversion of ROF is to the active R-NO. Formation/clearance processes of the R-NO appear to be slow with an observed tmax of 6.9 – 8.8 h, and corresponding to apparent t1/2 values of 22.7 h and 20.6 h, after IV and PO administration, respectively. Conclusion: ROF is rapidly absorbed after PO administration and exhibits high absolute bioavailability and low clearance pharmacokinetics. The total exposure of R-NO exceeds that of ROF by a factor of 12 after oral administration.Correspondence to:
Dr. T.D. Bethke
Medical Department
Nycomed Germany GmbH
Byk-Gulden-Straße 2
78467 Konstanz, Germany
Email: [email protected]
Extended Abstracts
The 8th Annual Meeting of CESAR in St. Gallen – Novel therapeutic concepts in hemato-oncology
R. Morant, D. Sehrt and U. Jaehde
Page No. 58
Abstract
The 8th Annual Meeting of CESAR in St. Gallen – Novel therapeutic concepts in hemato-oncology
R. Morant, D. Sehrt and U. Jaehde
Extended Abstracts
Cytotoxic effects of opioids on cancer cell lines
C. Friesen, S. Bacher, I. Hormann, M. Roscher and E. Miltner
Page No. 60
Abstract
Cytotoxic effects of opioids on cancer cell lines
C. Friesen, S. Bacher, I. Hormann, M. Roscher and E. Miltner
Extended Abstracts
Integrating predictive biomarkers and classifiers into oncology clinical development programs: an adaptive, evidence-based approach
R.A. Beckman
Page No. 63
Abstract
Integrating predictive biomarkers and classifiers into oncology clinical development programs: an adaptive, evidence-based approach
R.A. Beckman
Extended Abstracts
MRI Molecular imaging with albumin nanoparticles: achievements and challenges
G.C. Thurner, A.A. Abdelmoez, E.A. Wallnoefer, I. Rohr, N. Klammsteiner, H. Talasz, C. Kremser, W. Jaschke and P. Debbage
Page No. 65
Abstract
MRI Molecular imaging with albumin nanoparticles: achievements and challenges
G.C. Thurner, A.A. Abdelmoez, E.A. Wallnoefer, I. Rohr, N. Klammsteiner, H. Talasz, C. Kremser, W. Jaschke and P. Debbage
Extended Abstracts
Relevance of microRNA modulation in chemoresistant colon cancer in vitro
R.M. Mader, M. Wieser, W. Berger, M. Kalipciyan, M. Hackl, G.G. Steger and J. Grillari
Page No. 67
Abstract
Relevance of microRNA modulation in chemoresistant colon cancer in vitro
R.M. Mader, M. Wieser, W. Berger, M. Kalipciyan, M. Hackl, G.G. Steger and J. Grillari
Extended Abstracts
Suicide activation in a 5-fluorouracil resistant colon cancer model in vitro
R.M. Mader, M. Kalipciyan, P. Ohana, A. Hochberg and G.G. Steger
Page No. 69
Abstract
Suicide activation in a 5-fluorouracil resistant colon cancer model in vitro
R.M. Mader, M. Kalipciyan, P. Ohana, A. Hochberg and G.G. Steger
Extended Abstracts
Stable combretastatin A-4 analogues with sub-nanomolar efficacy against chemoresistant HT-29 cells
R. Schobert, K. Effenberger-Neidnicht and B. Biersack
Page No. 71
Abstract
Stable combretastatin A-4 analogues with sub-nanomolar efficacy against chemoresistant HT-29 cells
R. Schobert, K. Effenberger-Neidnicht and B. Biersack
Extended Abstracts
MRI molecular imaging with nanoparticles: a technical platform for early diagnosis of cancer
E.A. Wallnöfer, G.C. Thurner, A.A. Abdelmoez, I. Rohr, N. Klammsteiner, H. Talasz, C. Kremser, W. Jaschke and P. Debbage
Page No. 73
Abstract
MRI molecular imaging with nanoparticles: a technical platform for early diagnosis of cancer
E.A. Wallnöfer, G.C. Thurner, A.A. Abdelmoez, I. Rohr, N. Klammsteiner, H. Talasz, C. Kremser, W. Jaschke and P. Debbage
Extended Abstracts
Lysophosphatidylcholine (LPC) as a pharmacological molecule for the reduction of tumor cell adhesion and metastasis
M. Alexander, M. Schlesinger, P. Jantscheff, U. Massing and G. Bendas
Page No. 75
Abstract
Lysophosphatidylcholine (LPC) as a pharmacological molecule for the reduction of tumor cell adhesion and metastasis
M. Alexander, M. Schlesinger, P. Jantscheff, U. Massing and G. Bendas
Extended Abstracts
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents
H. Westekemper, M. Freistuehler, G. Anastassiou, G. Nareyeck, M. Zeschnigk, N. Bornfeld, K.-P. Steuhl, M.E. Scheulen and R.A. Hilger
Page No. 78
Abstract
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents
H. Westekemper, M. Freistuehler, G. Anastassiou, G. Nareyeck, M. Zeschnigk, N. Bornfeld, K.-P. Steuhl, M.E. Scheulen and R.A. Hilger
Extended Abstracts
Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro
I.E. Ratzenboeck, B. Bartl, B. Forstner, M. Kalipciyan, G.G. Steger and R.M. Mader
Price
42.00 $
Page No. 81
Abstract
Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro
I.E. Ratzenboeck, B. Bartl, B. Forstner, M. Kalipciyan, G.G. Steger and R.M. Mader
Extended Abstracts
Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential
M. Blaschke, S. Cameron, K. Emami, J. Blumberg, U. Wegner, M. Nischwitz and G. Ramadori
Page No. 83
Abstract
Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential
M. Blaschke, S. Cameron, K. Emami, J. Blumberg, U. Wegner, M. Nischwitz and G. Ramadori
Extended Abstracts
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR
R. Morant, V. Vuaroqueaux, P.A. Diener, G. Fürstenberger, C. Horica, T. Németh, M. Sulmoni, U. Eppenberger and S. Eppenberger-Castori
Page No. 86
Abstract
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR
R. Morant, V. Vuaroqueaux, P.A. Diener, G. Fürstenberger, C. Horica, T. Németh, M. Sulmoni, U. Eppenberger and S. Eppenberger-Castori
Extended Abstracts
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Page No. 88
Abstract
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Extended Abstracts
Choice and simulation of the randomization procedure for clinical trials
D. Schrimpf, L. Plotnicki and L.R. Pilz
Page No. 91
Abstract
Choice and simulation of the randomization procedure for clinical trials
D. Schrimpf, L. Plotnicki and L.R. Pilz
Extended Abstracts
Anti-inflammatory and anti-cancer activities of essential oils and their biological constituents
A. Torres Salazar, J. Hoheisel, M. Youns and M. Wink
Page No. 93
Abstract
Anti-inflammatory and anti-cancer activities of essential oils and their biological constituents
A. Torres Salazar, J. Hoheisel, M. Youns and M. Wink
Extended Abstracts
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
Page No. 96
Abstract
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
